Vyas Tungaturti is an M&A advisor with nearly two decades on the execution side of deals: first at Deloitte Consulting, then, since 2018, as an independent advisor to Big 4 firms on due diligence, integration and carve-outs across more than 50 transactions. He founded CorpDev.Org, runs CogTech, and builds Kai, AI-native due diligence for M&A and PE teams: upload a data room and within hours Kai has read every document, found every risk and opportunity, priced with evidence, and traced every figure to its source.
TL;DR
Prague-based Flowpay announced its acquisition of Berlin's Tapline on March 3, 2026, for undisclosed financial terms. The deal integrates Flowpay's traditional SME lending with Tapline's...
TL;DR
A consortium led by EQT and Global Infrastructure Partners (GIP) will take The AES Corporation private in an all-cash deal with an enterprise value of approximately $33.4 billion. The $15.00...
TL;DR
Telefónica Executive Chairman Marc Murtra is advocating for immediate regulatory relief on mergers in the European telecommunications sector to enable consolidation, which he argues is...
TL;DR
Medline Industries Inc.'s private equity sponsors, including Blackstone, Carlyle, and Hellman & Friedman, are divesting approximately 75 million Class A shares in a secondary offering...
TL;DR
Oaktree Capital Management is exploring a London IPO for its UK wealth solutions provider, Utmost Group, at a potential valuation of £2.5 billion ($3.3 billion). The private equity firm has...
TL;DR
Anthropic acquired Vercept, an AI startup specializing in agentic task automation, with the deal announced on February 26, 2026. While financial terms remain undisclosed, Anthropic secured...
TL;DR
Netflix has withdrawn its $83 billion offer for Warner Bros. Discovery's studio and streaming assets, clearing the path for Paramount Skydance's superior $111 billion bid to acquire the entire...
TL;DR
Sealed Air shareholders approved the company's acquisition by private equity firm Clayton, Dubilier & Rice (CD&R) for an enterprise value of approximately $5 billion. The all-cash deal...
TL;DR
Novo Nordisk entered a partnership with Vivtex Corp. valued at up to $2.1 billion to develop oral medicines for obesity and diabetes. The deal leverages Vivtex's proprietary drug delivery...
TL;DR
CalPERS, managing over $500 billion, maintains private equity as a core investment, targeting 13-15% allocation even after transitioning to a Third-Party Administrator (TPA) model in 2025. CEO...
